标题
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
作者
关键词
-
出版物
NATURE MEDICINE
Volume 25, Issue 12, Pages 1938-1947
出版商
Springer Science and Business Media LLC
发表日期
2019-12-03
DOI
10.1038/s41591-019-0668-z
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
- (2019) Rumani Singh et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase
- (2019) Blake E. Smith et al. Nature Communications
- Retromer facilitates the localization of Bcl-xL to the mitochondrial outer membrane
- (2019) Trey Farmer et al. MOLECULAR BIOLOGY OF THE CELL
- BCL-2 as therapeutic target for hematological malignancies
- (2018) Guilherme Fleury Perini et al. Journal of Hematology & Oncology
- Plasticity in binding confers selectivity in ligand-induced protein degradation
- (2018) Radosław P. Nowak et al. Nature Chemical Biology
- Interferon regulatory factor 8 regulates caspase-1 expression to facilitate Epstein-Barr virus reactivation in response to B cell receptor stimulation and chemical induction
- (2018) Dong-Wen Lv et al. PLoS Pathogens
- Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action
- (2018) Kristin M. Riching et al. ACS Chemical Biology
- Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas
- (2018) Raphael Koch et al. BLOOD
- Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?
- (2017) Ian Churcher JOURNAL OF MEDICINAL CHEMISTRY
- Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells
- (2017) D T Saenz et al. LEUKEMIA
- Structural basis of PROTAC cooperative recognition for selective protein degradation
- (2017) Morgan S Gadd et al. Nature Chemical Biology
- From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors
- (2017) Avi Ashkenazi et al. NATURE REVIEWS DRUG DISCOVERY
- Protein Knockdown Technology: Application of Ubiquitin Ligase to Cancer Therapy
- (2016) Nobumichi Ohoka et al. CURRENT CANCER DRUG TARGETS
- Chemical genetics approaches for selective intervention in epigenetics
- (2016) Andrew C Runcie et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Venetoclax: First Global Approval
- (2016) Emma D. Deeks DRUGS
- Patient-derived xenografts: a relevant preclinical model for drug development
- (2016) Luca Pompili et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
- (2016) András Kotschy et al. NATURE
- The Perseus computational platform for comprehensive analysis of (prote)omics data
- (2016) Stefka Tyanova et al. NATURE METHODS
- Induced protein degradation: an emerging drug discovery paradigm
- (2016) Ashton C. Lai et al. NATURE REVIEWS DRUG DISCOVERY
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
- (2016) Andrew W. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
- (2016) Kanak Raina et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Computationally designed high specificity inhibitors delineate the roles of BCL2 family proteins in cancer
- (2016) Stephanie Berger et al. eLife
- Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
- (2015) Michael Zengerle et al. ACS Chemical Biology
- Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL
- (2015) Ashton C. Lai et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- The BCL-2 protein family, BH3-mimetics and cancer therapy
- (2015) A R D Delbridge et al. CELL DEATH AND DIFFERENTIATION
- Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
- (2015) Jing Lu et al. CHEMISTRY & BIOLOGY
- Attacking cancer's Achilles heel: antagonism of anti-apoptotic BCL-2 family members
- (2015) Joseph T. Opferman FEBS Journal
- Prime time for PROTACs
- (2015) Raymond J Deshaies Nature Chemical Biology
- Catalytic in vivo protein knockdown by small-molecule PROTACs
- (2015) Daniel P Bondeson et al. Nature Chemical Biology
- Phthalimide conjugation as a strategy for in vivo target protein degradation
- (2015) G. E. Winter et al. SCIENCE
- Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
- (2015) Joel D. Leverson et al. Science Translational Medicine
- Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia
- (2014) Aksana Kaefer et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity
- (2014) Zhi-Fu Tao et al. ACS Medicinal Chemistry Letters
- Only severe thrombocytopenia results in bleeding and defective thrombus formation in mice
- (2013) M. Morowski et al. BLOOD
- The complex transcriptional landscape of the anucleate human platelet
- (2013) Paul F Bray et al. BMC GENOMICS
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Next Generation Sequencing Analysis of Human Platelet PolyA+ mRNAs and rRNA-Depleted Total RNA
- (2013) Antheia Kissopoulou et al. PLoS One
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- Targeting the Bcl-2 family for cancer therapy
- (2012) Shibu Thomas et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- The Proteomics Identifications (PRIDE) database and associated tools: status in 2013
- (2012) Juan Antonio Vizcaíno et al. NUCLEIC ACIDS RESEARCH
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- BCL2/BCL-XL inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation
- (2011) M. Vogler et al. BLOOD
- Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets
- (2011) S. M. Schoenwaelder et al. BLOOD
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo
- (2011) J. Chen et al. MOLECULAR CANCER THERAPEUTICS
- The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo
- (2010) Scott Ackler et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Mcl-1 and Bcl-xL cooperatively maintain integrity of hepatocytes in developing and adult murine liver
- (2009) Hayato Hikita et al. HEPATOLOGY
- Universal sample preparation method for proteome analysis
- (2009) Jacek R Wiśniewski et al. NATURE METHODS
- Bcl-2-family proteins and hematologic malignancies: history and future prospects
- (2008) J. C. Reed BLOOD
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- (2008) C. Tse et al. CANCER RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started